http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#Head http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#provenance http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#pubinfo http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion http://purl.obolibrary.org/obo/DOID_0060224 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_0060224 http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00489 http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association http://www.w3.org/2000/01/rdf-schema#label sotalol hydrochloride tablets usp are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are life threatening because of the proarrhythmic effects of sotalol hydrochloride tablets see warnings initiation of sotalol hydrochloride tablet usp treatment or increasing doses as with other antiarrhythmic agents used to treat life threatening arrhythmias should be carried out in the hospital the response to treatment should then be evaluated by a suitable method e g pes or holter monitoring prior to continuing the patient on chronic therapy various approaches have been used to determine the response to antiarrhythmic therapy including sotalol hydrochloride tablets usp in the esvem trial response by holter monitoring was tentatively defined as 1 suppression of ventricular tachycardia 9 suppression of non sustained vt 8 suppression of paired vpcs and 75 suppression of total vpcs in patients who had at least 1 vpcs hour at baseline this tentative response was confirmed if vt lasting 5 or more beats was not observed during treadmill exercise testing using a standard bruce protocol the pes protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites response by pes was defined as prevention of induction of the following 1 monomorphic vt lasting over 15 seconds 2 non sustained polymorphic vt containing more than 15 beats of monomorphic vt in patients with a history of monomorphic vt 3 polymorphic vt or vf greater than 15 beats in patients with vf or a history of aborted sudden death without monomorphic vt and 4 two episodes of polymorphic vt or vf of greater than 15 beats in a patient presenting with monomorphic vt sustained vt or nsvt producing hypotension during the final treadmill test was considered a drug failure in a multicenter open label long term study of sotalol hydrochloride tablets usp in patients with life threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications response by holter monitoring was defined as in esvem response by pes was defined as non inducibility of sustained vt by at least double extrastimuli delivered at a pacing cycle length of 4 msec overall survival and arrhythmia recurrence rates in this study were similar to those seen in esvem although there was no comparative group to allow a definitive assessment of outcome antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias sotalol is also indicated for the maintenance of normal sinus rhythm delay in time to recurrence of atrial fibrillation atrial flutter afib afl in patients with symptomatic afib afl who are currently in sinus rhythm and is marketed under the brand name betapace af sotalol hydrochloride tablets usp are not approved for the afib afl indication and should not be substituted for betapace af because only betapace af is distributed with a patient package insert that is appropriate for patients with afib afl http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00489 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#provenance http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#pubinfo http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig http://purl.org/nanopub/x/hasSignature I/n/RqGCpDq+orpUprVePQDe8SPvxwurPNlTMIKCFoL+1WNYdHO5QDpsxY41gZgWM4u6C1f1V3mJZnG8iiyoL+KxsraqOsqNB9cYWAlni/HJLoNivDOoKSM127Uyo0bSfO0VYdvGBWkc6T/QMfwFYV6bdQvIYVltQqOqexTvFuQ= http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://purl.org/dc/terms/created 2021-07-03T11:35:14.650+02:00 http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs